PlainPharmaWatch

CMS Open Payments · Program Year 2024

Asklepios Biopharmaceutical Inc.

Asklepios Biopharmaceutical Inc. reported $7,615,401.57 in payments to 11 physicians and teaching hospitals across 11 transactions.

See the rankings → How this is sourced
$7.6M
Total payments
11
Transactions
11
Recipients
−$1.1M
General Payments vs PY2023

Asklepios Biopharmaceutical Inc. reported $7,615,401.57 in payments to 11 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #214 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $692.3K per recipient across 1 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Asklepios Biopharmaceutical Inc. pairs top-quartile payment volume with a moderately concentrated payment pattern.

#214
of 1,925 companies
0.1%
of all US industry payments
0.5%
paid to its single top recipient
1
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Asklepios Biopharmaceutical Inc.'s CMS-reported General Payments decreased by $1.1M (−13.0%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2023: ASKLEPIOS BIOPHARMACEUTICAL INC.PY2024: Asklepios Biopharmaceutical Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$8.8MPY2024$7.6M
PY2023
$8,753,052.23
PY2024
$7,615,401.57

How Asklepios Biopharmaceutical Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Asklepios Biopharmaceutical Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$7,615,402 Top 11% higher than 89% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). This entry sits in this band. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Asklepios Biopharmaceutical Inc.

$7,615,401.57: that is what Asklepios Biopharmaceutical Inc. reported in payments to 11 physicians and teaching hospitals during Program Year 2024, spread across 11 transactions ($692.3K per transaction, $692.3K per recipient). The company sits at rank #214 of 1,925, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.

Of the 1 general-payment categories charted below, "Acquisitions" is the largest at $7.6M across 11 transactions, 100.0% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Asklepios Biopharmaceutical Inc. made 1 types of general payments. "Acquisitions" is the largest category at $7.6M, 100.0% of the company's reported total.

How Asklepios Biopharmaceutical Inc. divides its payments

Ranked by total dollars reported per category

1. Acquisitions$7.6M
Payment Type Amount Transactions
Acquisitions $7.6M 11

Recipient Concentration in General Payments

The five largest recipient relationships account for $7,244,557.42 (95.1%) of $7,615,401.57 in this company's General Payments records across 11 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Asklepios Biopharmaceutical Inc.

The five named recipients with the highest reported General Payments from this company

Dwight D Koeberl$3.4MRoger Hajjar$2.1MPriya S Kishnani$1.3MMassimo Fiandaca$236.4KAmber D Van Laar$168.8K
  1. 1

    Dwight D Koeberl

    $3,431,676.01 across 1 reported transactions

  2. 2

    Roger Hajjar

    $2,114,077.40 across 1 reported transactions

  3. 3

    Priya S Kishnani

    $1,293,621.29 across 1 reported transactions

  4. 4

    Massimo Fiandaca

    $236,356.58 across 1 reported transactions

  5. 5

    Amber D Van Laar

    $168,826.14 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $692.3K. Average per recipient: $692.3K.

Total Amount

$7,615,401.57

Avg per Transaction

$692.3K

Avg per Recipient

$692.3K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Asklepios Biopharmaceutical Inc. Share

0.1%

#214 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Asklepios Biopharmaceutical Inc.

DuraStat LLC

$7.6M 0 recipients

Straumann USA LLC

$7.6M 35,784 recipients

Penumbra, Inc.

$7.7M 22,427 recipients

Exeltis, USA Inc.

$7.7M 17,662 recipients

Integrity Orthopaedics, Inc.

$7.7M 173 recipients

Skye Orthobiologics LLC

$7.4M 38 recipients

Frequently Asked Questions

How much did Asklepios Biopharmaceutical Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $7,615,401.57 from Asklepios Biopharmaceutical Inc. to physicians and hospitals across 11 transactions - 0.1% of all industry payments reported that year.
How many physicians received payments from Asklepios Biopharmaceutical Inc.? ▾
Asklepios Biopharmaceutical Inc. made payments to 11 physicians and teaching hospitals in 2024. The average payment per recipient was $692.3K.
What types of payments did Asklepios Biopharmaceutical Inc. make? ▾
General payments from Asklepios Biopharmaceutical Inc. span 1 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Acquisitions" at $7.6M, representing 100.0% of the company's reported total.
How does Asklepios Biopharmaceutical Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Asklepios Biopharmaceutical Inc. ranks #214 by total payment amount.
What is the average payment size from Asklepios Biopharmaceutical Inc.? ▾
Asklepios Biopharmaceutical Inc.'s 11 transactions to 11 recipients in 2024 averaged $692.3K per transaction.
Where does the payment data for Asklepios Biopharmaceutical Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Asklepios Biopharmaceutical Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.